



Project Updates

Effectiveness and Cost-Effectiveness Assessment of Heart Failure Clinics in Ontario

The overall research question for this field evaluation is to understand the current service models used and to evaluate the clinical effectiveness and cost-effectiveness of heart failure (HF) clinics for the ambulatory management of HF in Ontario.

Final report was submitted on December 2011.

Pressure Ulcer Multi-Disciplinary Teams via Telemedicine (PUMTT): A Cluster Pragmatic Randomised Controlled Trial

The purpose of this field evaluation is to evaluate the clinical and cost effectiveness of 'enhanced' multi-disciplinary wound care teams vs. 'usual' care teams in long term care (LTC) homes in the Greater Toronto Area for the treatment of pressure ulcers.

Data collection closed in April this year. 138 residents with 270 pressure ulcers were recruited from 12 long-term care facilities in the greater Toronto area. Quantitative and qualitative data were collected throughout the study period. Data analysis is underway and report will be ready this September.

Turning for Ulcer Reduction (TURN) Study

Recruitment was completed in the US on June, 23.

967 subjects were recruited into this randomized controlled trial, led by Dr. Nancy Bergstrom from the University of Texas. The final report will be submitted this month, with results being presented to OHTAC on June 22nd.

Academic Rounds

Many thanks to past presenters:

Mona Sabharwal
Farzad Ali
Mireille Goetghebeur
Dante Morra
Christopher Hollenbeak
Tina Shih
Rumona Dickson
Petros Pechlivanoglou

Please check
theta.utoronto.ca
for upcoming
Rounds



Project Updates

Specialized Multidisciplinary Community-Based Care for Chronic Wounds: A Field Evaluation

The objective of this field evaluation is to: 1) identify all out-patient multidisciplinary wound care teams (MWCTs) across the province; 2) conduct a survey in order to understand the scope of service models of the identified MWCTs ; 3) evaluate the clinical effectiveness ; and 4) evaluate the cost effectiveness.

This field evaluation has 3 phases: Phase 1: Identification of teams; Phase 2: Survey of teams; Phase 3: Pragmatic randomized controlled trial to evaluate clinical effectiveness, and cost effectiveness of MWCTs.

Phases 1 and 2 are complete. A total of 49 teams were identified and 44 teams participated in the phase 2 surveys. Phase 3 began in May, 2011 and thus far 26 participants have been recruited. Data collection is expected to continue for two years. A total of 450 participants will be recruited.

You can read more about THETA's projects [here](#).

In the Spotlight



Thank you Dr. Jeff Hoch for coordinating the THETA Rounds in the past 5 years. We really appreciate all your hard work! A gift token was presented to Jeff at the last THETA rounds for the curriculum year on May 4, 2012. We welcome Beate Sander, our new THETA Rounds Coordinator beginning September 2012.

THETA “KT to Policy” Day & Fifth Annual Symposium

THETA recently hosted two back-to-back events at The Estates of Sunnybrook – THETA’s Third Annual “Knowledge Translation to Policy” Day on May 10th and THETA’s Fifth Annual Symposium on May 11th.

KT Day focussed on our work in the area of *Chronic Wound Prevention & Wound Care Delivery*, while the Symposium focused on *Disinvestment in Ontario Health Care*.

Each event was attended by over 90 delegates who represented diverse local, national and international organizations and backgrounds, including universities, research institutes, provincial organisations and hospitals, various academic departments, THETA staff, students, and government.

THETA KT Day



THETA Symposium



THETA Collaborative would like to thank everyone for attending. Once again, both events proved to be very successful, with an excellent turnout, beautiful weather, and really great external and local speakers.

Presentation material can be found [here](#).



Research Grants

A National Comparison of Intensity of End-of-Life Care in Canada: Defining Changing Patterns, Risk Factors and Targets for Intervention

\$99,208 (2011 – 2013)

PI: Fowler R.

Council of Academic Hospitals of Ontario (CAHO) Implementation of Antimicrobial Stewardship Programs (ASP) in Intensive Care Units in Ontario Academic Hospitals

\$768,000 (2011 – 2013)

PI: Andrew Morris.

Co-Investigators: Fowler R, Bell C, Burry L, Daneman N, Dresser L, Elligsen M, Herridge M, Mehta S, Muller M.

DECision-making about goals of care for hospitalized medical patients: a multicentre, mixed-methods study. The DECIDE Study

\$100,000 (2012 – 2014)

PIs: Heyland D, You J.

Co-Investigators: Fowler R, Albert M, Brazil K, Day A, Downar J, Ilan R, Jayaraman D, Kryworuchko J, Lamontagne F, Ma I, Palepu A, Shik J, Strachan P.

Estimating the risk of adverse drug events using Bayesian evidence synthesis

Canadian Institutes of Health Research (CIHR) Drug Safety and Effectiveness Network (DSEN) (2012-2013)

Nominated Principal Investigator: John-Baptiste A; *Principal Investigator:* Austin P.

Co-investigators: Anderson G, Lipscombe L, Becker T.

Ministry of Health and Long-term Care Drug Innovation Fund – Paediatric Pharmacogenomics Medicine, GeneMed

\$589,697 (Oct 2011 – Sep 2014)

Co-PIs: Ito S & Ungar J

Co-Investigators: Hitzler J, Hurdowar A, Moore A, Koren G

Phase-Specific and Lifetime Medical Costs of Care for Childhood Cancer in British Columbia and Ontario

CIHR, \$531,058 (Apr 2012 – Mar 2015)

Co-PIs: McBride M & Krahn M.

Co-Investigators: de Oliveira C, Greenberg M, Nathan P, Peacock S, Rogers P.

Planning meeting for the PREEDICCT study

CIHR, \$23,842 (2011 – 2012)

PI: Christian M

Co-Investigators: Fisman D, Fowler R, Marshall J, Zygun D.

Reducing inequalities in the burden of human papillomavirus (HPV) related diseases in Canada through optimal vaccination and screening policies: A multidisciplinary model-based approach

CIHR, \$662,657 (2012 – 2015); *PI:* Brisson M

The Canadian Institutes of Health Research: “A systematic review of factors influencing older adults’ decision to accept or refuse cancer treatment proposed by their physician.”

\$51,835 (April 2012 – March 2013)

Co-PI: Alibhai S, Puts M, Fitch M, Howell D, Krzyzanowska M, Leighl N, Monette J, Wan-Chow-Wah D.

The Leukemia and Lymphoma Society (US): “Long-term QOL, physical function, and disability in AML survivors.”

\$579,369 (Oct 2011 – Sep 2014)

PI: Alibhai S

Co-Investigators: Brandwein J, Buckstein R, Gupta V, Li M, Tomlinson G.



Publications

Alibhai SMH, Yun L, Paszat L, Cheung AM (2012). Screening for osteoporosis in men on androgen deprivation therapy. *JAMA*, 307(3):255-6.

Andradóttir S, Chiu W, Goldsman D, Lee ML, Tsui KL, **Sander B**, Fisman DN, Nizam A. (2011). Reactive strategies for containing developing outbreaks of pandemic influenza. *BMC Public Health*, 11;Suppl 1(S1).

Arino J, Bauch C, Brauer F, Driedger SM, Greer AL, Moghadas SM, Pizzi NJ, **Sander B**, Tuite A, van den Driessche P, Watmough J, Wu J. (2011). Pandemic Influenza: Modelling and Public Health Perspectives. *Mathematical Biosciences and Engineering*, 8(1):1-20.

Chan KK, Siu E, **Krahn M**, Imrie K, **Alibhai SMH** (2012). A cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. *Journal of Clinical Oncology*, 30(10):1064-71.

Culyer AJ, Bombard Y (2011). An equity framework for health technology assessments. Forthcoming in *Medical Decision Making*.

Culyer AJ (2011). Maximising the odds. *New Statesman* (supplement: Competition in a New Society: National Health), 15 December, 6-8.

Culyer AJ (2012). Hic sunt dracones: the future of Health Technology Assessment – one economist's perspective. *Medical Decision Making*, 32: E25-E32.

Daneman N, Shore K, Pinto R, **Fowler RA** (2011). Antibiotic treatment duration for bloodstream infections in critically ill patients: a national survey of Canadian infectious diseases and critical care specialists. *Int J Antimicrob Agents*, Dec;38(6):480-5.

Donnan JR, **Ungar WJ**, Mathews M, Rahman P (2011). Systematic review of thiopurine methyltransferase genotype and enzymatic testing strategies. *Therapeutic Drug Monitoring*, 33:192-199.

Evans TW, Nava S, Mata GV, Guidet B, Estenssoro E, **Fowler RA**, Scheunemann LP, White D, Manthous CA (2011). Critical care rationing: international comparisons. *Chest*, Dec;140(6):1618-24.

Gupta V, Panzarelli T, Li L, Khan J, Sharma A, Lipton JH, Kuruvilla J, Messner H, **Alibhai SMH** (2012). A prospective study comparing the outcomes and health-related quality of life in adult patients with myeloid malignancies undergoing allogeneic transplantation using myeloablative or reduced-intensity conditioning. *Blood and Bone Marrow Transplantation*, 18(1):113-24.

Mostaço-Guidolin LC, Greer A, **Sander B**, Wu J, Moghadas S (2011). Variability in Transmissibility of the 2009 H1N1 Pandemic in Canadian Communities. *BMC Research Notes*, 4(1):537.

Pereira JA, Heidebrecht CL, Quach S, Quan SD, Finkelstein M, Bettinger JA, Deeks SL, Guay M, Buckeridge DL, Chambers L, Crowcroft NS, **Sander B**, Kalailieff D, Brien S, Kwong JC (2011). Influenza Immunization Data: Can We Make Order Out of Chaos? *Healthcare Quarterly*, 14(4), 6-7.

Pereira JA, Foisy J, Kwong JC, Heidebrecht CL, Quach S, Quan SD, Guay M, **Sander B** (2011). A cost comparison of electronic and hybrid data collection systems in Ontario during pandemic and seasonal influenza vaccination campaigns. *BMC Health Services Research*, 11(210).

Pham B, Stern A, Chen W, Sander B, John-Baptiste A, Thein H-H, Gomes T, Wodchis W, Bayoumi A, Machado M, Carcone S, Krahn M (2011). Preventing Pressure Ulcers in Long-Term Care: A Cost-Effectiveness Analysis. *Archives of Internal Medicine*, 171(20):1839-1847.

Teuffel O, Cheng S, Sung L, Ethier MC, Diorio C, Martino J, Mayo C, Regier D, Wing R, **Alibhai SMH** (2012). Health related quality of life anticipated with different management strategies for adult febrile neutropenia. *Supportive Care in Cancer*, epub Feb 17.

Thirugnanam S, Pinto R, Cook DJ, Geerts WH, **Fowler RA** (2012). Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review. *Critical Care*, 16(2):R43.

Tomlinson G, Bremner KE, Ritvo P, Naglie G, Krahn MD (2012). Development and Validation of a Utility Weighting Function for the Patient-Oriented Prostate Utility Scale (PORPUS). *Medical Decision Making*, 32(1):11-30.

Ungar WJ (2012). Medication cost-sharing and health outcomes in children with asthma. *JAMA*, March; 307(12):1316-1318.

Ungar WJ (2011). Challenges in health state valuation in pediatric economic evaluation: Are QALYs contraindicated? *Pharmacoeconomics*, 29(8):641-652.

Wagstaff Adam & **Culyer AJ** (2011). Four Decades of Health Economics through a Bibliometric Lens. World Bank Policy Research Working Paper Series, 5829 (forthcoming in *Journal of Health Economics*).

Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D (2012). A review of the cost of atrial fibrillation. *Value in Health*, Mar;15(2):240-8.

Yap S, **Alibhai SMH**, Abouassaly R, Cheung H, Timilshina N, Finelli A (2012). Do we continue to unnecessarily perform ipsilateral adrenalectomy at the time of radical nephrectomy? - A population-based study. *Journal of Urology* 2012; 187(2):398-404.



Have a fun & safe summer!



Leslie Dan Pharmacy Building
University of Toronto
6th Floor, Room 658
144 College Street
Toronto, Ontario Canada M5S 3M2
T 416 946 3718
F 416 946 3719
E info@theta.utoronto.ca